Acura -6.4% AH after providing update for Aversion

The FDA has advised Acura (ACUR) that data from its AP-ADF-301 intranasal abuse liability study for its Aversion combo drug is "insufficient to support an intranasal abuse deterrence claim."

Acura says its plans for the drug, including "a revised projected timeline" for submitting an NDA, will be determined following a meeting with the FDA.

The company adds it's "committed to developing [its] Aversion opiods products."

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs